

IS IT TIME TO CONSIDER MOVING TOWARDS FLUCELVAX[®] – a cell-based vaccine?*



FLUCELVAX[®] & FLUCELVAX[®] QUAD – THE FIRST INFLUENZA VACCINE FRANCHISE FOR CANADIANS USING CELL-BASED TECHNOLOGY^{1**}

Cell-based manufacturing refers to how the flu vaccine is made. Influenza viruses used in the cell-based vaccine are grown in cultured mammalian cells. Cell-based technology allows for cell banking which assures an adequate supply of cells is readily available for vaccine production.²

FLUCELVAX[®] is a trivalent inactivated vaccine indicated for active immunization of adults and children aged 6 months or older for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.³

FLUCELVAX[®] QUAD is a quadrivalent inactivated vaccine indicated for active immunization of adults and children aged 6 months or older for the prevention of influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.⁴

GUIDELINE RECOMMENDATIONS



NACI

The National Advisory Committee on Immunization (NACI) recommends cell-culture based inactivated influenza vaccines (IIV-cc), among other influenza vaccines, for adult and children aged 6 months to less than 65 years.⁵



CPS

The Canadian Paediatric Society (CPS) encourages annual influenza vaccination for all children and youth 6 months of age or older.⁶



SOGC & NACI

The Society of Obstetricians and Gynecologists of Canada (SOGC) recommends that **all pregnant women, at any stage in pregnancy, or women who might be pregnant in the upcoming influenza season**, should be offered an inactivated influenza vaccine.⁷

The NACI also strongly recommends that cell-culture based inactivated influenza vaccine, among other influenza vaccines, should be offered to pregnant individuals at any stage of pregnancy.^{8**}

* The trivalent formulation of IIV-cc was not part of the NACI assessment.

[§] Healthcare providers should assess the benefit and potential risks of administering the vaccine to pregnant women taking into consideration official recommendations. The safety of FLUCELVAX[®] in pregnancy has not been assessed in randomized clinical trials.

* Clinical significance has not been established.

** Comparative clinical significance has not been established.



FREQUENTLY ASKED QUESTIONS

Are all flu vaccines the same in terms of their manufacturing process?

No. For example, FLUCELVAX® & FLUCELVAX® QUAD are flu vaccines made using cell-based technology, the first franchise of its kind in Canada.^{1†}

Is FLUCELVAX® only for patients with egg allergies?

No. FLUCELVAX® can be used for all eligible patients 6+ months.³

Is FLUCELVAX® appropriate for all my patients?

FLUCELVAX® is authorized for use in eligible children 6+ months and eligible adults.³

Is the FLUCELVAX® franchise newly available in Canada?



FLUCELVAX® QUAD has been available in Canada since:⁹

- 2019 for adults and children 9+ years
- 2021 for children 2+ years
- 2022 for children 6+ months

FLUCELVAX® is available in Canada.³

What format is FLUCELVAX® available in?

FLUCELVAX® is conveniently available in prefilled syringes (PFS).³

FLUCELVAX® does not contain antibiotics.³

What is the experience of FLUCELVAX® worldwide?

Over 300 million doses of FLUCELVAX® & FLUCELVAX® QUAD have been distributed worldwide.^{1†}

Does FLUCELVAX® have any real-world evidence?

FLUCELVAX® is currently being investigated in ongoing real-world studies, with over 100,000 patients.^{1†}

Relevant warnings and precautions:

- As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine
- Postpone in patients with febrile illness
- Clinically significant bleeding disorders
- Endogenous or iatrogenic immunosuppression
- Guillain-Barré syndrome
- Syncope, presyncope
- Pregnant and nursing women
- A protective immune response may not be elicited in all vaccine recipients

For more information:

Please consult the Product Monograph at health-products.canada.ca/dpd-bdpp/ for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling us at 1-855-358-8966.

* Clinical significance has not been established.

† Comparative clinical significance has not been established.

Visit flucelvax.ca/hcp for more information

1. Data on file.
2. CDC. Cell-Based Flu Vaccines. www.cdc.gov/flu/prevent/cell-based.htm (accessed Feb 1, 2020).
3. FLUCELVAX® Product Monograph.
4. FLUCELVAX® QUAD Product Monograph.
5. National Advisory Committee on Immunization. Statement on Seasonal Influenza Vaccine for 2025–2026. 2025.

6. Canadian Paediatric Society. Vaccine recommendations for children and youth for the 2023/2024 influenza season.
7. SOGC Clinical Practice Guideline. No.357–Immunization in Pregnancy. 2018.
8. National Advisory Committee on Immunization. Updated Guidance on Influenza Vaccination During Pregnancy. 2023.
9. FLUCELVAX® QUAD Notice of Compliance. Health Canada.

CSL Seqirus

CSL Seqirus Canada
Kirkland, Québec
www.CSLseqirus.ca

1.844.392.8582 514.221.4877

© 2025 Seqirus. All rights reserved.
Seqirus is a trademark of Seqirus U.K. Limited or its affiliates.
FLUCELVAX® is a registered trademark of Seqirus UK Limited or its affiliates. Product Monograph available on request
CAN-FCV-25-0002



FLUCELVAX®
Influenza Vaccine (surface antigen, inactivated, prepared in cell cultures)